Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients.
URBANA — Legal wars over property taxes. Financial woes announced by the mother health system. Complaints from state employees frustrated over Illinois not paying health care bills.
Is there a doctor in the CEO's office?
For information about services available to older adults, contact Karen Graves, director of the Retired and Senior Volunteer Program (RSVP) and Helen Mary Stevick Senior Citizens Center, 48 E. Main St., Champaign, IL 61820, phone 359-6500.
RSVP and the Stevick Senior Center are administered by Family Service of Champaign County.
URBANA — A dean for the future Carle Illinois College of Medicine is now expected to be hired by early October, a search that's taken longer than expected because of scheduling issues and the complex nature of the job.
CHICAGO (AP) — Higher prices and fewer choices on the Illinois marketplace under President Barack Obama's health insurance law will make choosing a plan for 2017 a potentially frustrating experience for families who buy their own coverage, according to information released Wednesday by the Illinois Department of Insurance.
Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has climbed more than 600 percent over the past decade.
NEW YORK (AP) — Valeant Pharmaceuticals replaced Robert Rosiello as chief financial officer as the embattled company attempts to normalize operations amid a host of investigations and class action lawsuits.
The Canadian company named Paul Herendeen, former Zoetis chief financial officer, to fill the post immediately on Monday.
CHICAGO (AP) — There are no bomb blasts or collisions with burly linemen in Susan Contreras' past. Her headaches, memory loss and bouts of confused thinking were a mystery until doctors suggested a probable cause: domestic violence.
A former partner repeatedly beat her, she says.
Pfizer will pay about $14 billion in cash for the cancer drug company Medivation, a deal that will add the pricey late-stage prostate cancer treatment Xtandi to its oncology portfolio.
The New York drugmaker said Monday that it will pay $81.50 per Medivation share. That's a 21 percent premium to the San Francisco biotech's Friday closing price of $67.19.
Deanna Terven was inspired to write this essay after reading Bill Lyon's series on living with Alzheimer's. Those stories ran in The News-Gazette Commentary section on June 12 and 26, and July 10, 17 and 24.
By Deanna Terven